Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative zoledronate in p53-selected triple-negative breast cancer
2014-004194-16Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronate in breast cancer and triple-negative breast cancer (TNBC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Ki67 response rate. Started May 2015; status: completed.
02
Drugs
zoledronate
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-004194-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004194-16.